BioSpace News Archive

Abeona Therapeutics Inc. announced the closing of its underwritten public offering, with a gross offering size of approximately $103.5 million, which includes the full exercise of the underwriters’ option to purchase 5,400,000 additional shares of common stock, at a public offering price of $2.50 per share.

Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis

Research indicates that the five major European countries are experiencing varying trends in commercializing Oncology biosimilars and Immunology biosimilars

bioLIVE China 2020, will be held again at Hall W4 in the SNIEC on June 22-24, 2020.